D. Milenic

发表

Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant

T. Yokota, P. Hand, J. Schlom, 2005, Cancer Immunology, Immunotherapy.

Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent

M. Brechbiel, D. Milenic, D. Milenic, 2009, British journal of pharmacology.

Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.

M. Brechbiel, D. Milenic, Hyun-soon Chong, 2008, Journal of medicinal chemistry.

Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.

M. Brechbiel, D. Milenic, D. Cheng, 2008, Bioconjugate chemistry.

Antibody-targeted radiation cancer therapy

M. Brechbiel, D. Milenic, E. Brady, 2004, Nature Reviews Drug Discovery.

In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.

M. Brechbiel, D. Milenic, K. Garmestani, 2006, Nuclear medicine and biology.

Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.

P. Choyke, T. Nayak, M. Brechbiel, 2013, Radiology.

Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

M. Brechbiel, D. Milenic, K. Garmestani, 2008, Cancer biotherapy & radiopharmaceuticals.

Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies.

J. Schlom, J. Carrasquillo, P. Ferroni, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Potential for Artifacts in Monitoring for the Detection of Tumor Associated Antigens (TAG-72 and CEA) in Serum from Patients Undergoing MAb-based Diagnostic and Therapeutic Protocols

J. Schlom, J. Carrasquillo, P. Ferroni, 1990, The International journal of biological markers.

Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

T. Yokota, J. Schlom, M. Whitlow, 1992, Cancer research.

Monoclonal Antibody Targeted Radiation Cancer Therapy

M. Brechbiel, D. Milenic, E. Brady, 2007 .

Targeting of Radio-Isotopes for Cancer Therapy

M. Brechbiel, D. Milenic, 2004, Cancer biology & therapy.

Novel chelating agents for potential clinical applications of copper.

M. Brechbiel, D. Milenic, D. Ma, 2002, Nuclear medicine and biology.

In vivo tumor targeting of a recombinant single-chain antigen-binding protein.

K. D. Hardman, J. Schlom, M. Pantoliano, 1990, Journal of the National Cancer Institute.

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.

L. Chappell, M. Brechbiel, J. Schlom, 2002, Nuclear medicine and biology.

Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies.

S. Mirzadeh, M. Brechbiel, J. Schlom, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from 177Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts

M. Brechbiel, D. Milenic, K. Baidoo, 2016, International journal of molecular sciences.

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

E. Padlan, P. Hand, J. Schlom, 1995, Hybridoma.

A CDR-grafted (humanized) domain-deleted antitumor antibody.

P. Hand, J. Schlom, D. Milenic, 1997, Cancer biotherapy & radiopharmaceuticals.

Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.

J. Schlom, A. Molinolo, M. Roselli, 1995, Anticancer research.

Impact of α-Targeted Radiation Therapy on Gene Expression in a Pre-Clinical Model for Disseminated Peritoneal Disease when Combined with Paclitaxel

M. Brechbiel, D. Milenic, K. Baidoo, 2014, PloS one.

Monoclonal antibody-based therapy strategies: providing options for the cancer patient.

D. Milenic, 2002, Current pharmaceutical design.

Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography.

M. Brechbiel, D. Milenic, G. L. Ray, 2012, Molecular pharmaceutics.

Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers.

P. Choyke, M. Brechbiel, M. Bernardo, 2008, Molecular pharmaceutics.

Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease

M. Brechbiel, P. Albert, D. Milenic, 2007, Clinical Cancer Research.

Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.

M. Brechbiel, D. Milenic, K. Baidoo, 2013, International journal of radiation oncology, biology, physics.

Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease

M. Brechbiel, D. Milenic, K. Baidoo, 2015, mAbs.

Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma

T. Nayak, M. Brechbiel, D. Milenic, 2010, Journal of Nuclear Medicine.

PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1–Targeted 89Zr-Labeled Panitumumab

T. Nayak, M. Brechbiel, D. Milenic, 2012, The Journal of Nuclear Medicine.

In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.

S. Larson, J. Schlom, J. Carrasquillo, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI.

M. Brechbiel, D. Milenic, L. H. Bryant, 2011, Journal of inorganic biochemistry.

A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin.

M. Brechbiel, D. Milenic, K. Garmestani, 2002, Nuclear medicine and biology.

In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand

M. Brechbiel, J. Schlom, J. Carrasquillo, 1998, European Journal of Nuclear Medicine.

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab

T. Nayak, M. Brechbiel, D. Milenic, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

M. Brechbiel, D. Milenic, K. Baidoo, 2018, Cancer biotherapy & radiopharmaceuticals.

Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.

G. Curt, J. Schlom, J. Carrasquillo, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent.

M. Brechbiel, J. Frank, B. Lewis, 2015, Bioorganic & medicinal chemistry letters.

Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.

S. Larson, V. Reuter, H. Scher, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Actinium-225 Conjugates of MAb CC49 and Humanized ΔCH2CC49

S. Kennel, S. Mirzadeh, M. Brechbiel, 2002 .

Methodology for labeling proteins and peptides with lead-212 (212Pb).

M. Brechbiel, D. Milenic, K. Baidoo, 2013, Nuclear medicine and biology.

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.

P. Hand, J. Schlom, J. Carrasquillo, 1995, Cancer research.

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.

E. Padlan, J. Schlom, D. Milenic, 1999, Molecular immunology.

Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

M. Brechbiel, A. Molinolo, D. Milenic, 2015, Pharmaceuticals.

Characterization of Primate Antibody Responses to Administered Murine Monoclonal Immunoglobulin

D. Milenic, J. Reynolds, D. Colcher, 1990, The International journal of biological markers.

Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas.

D. Milenic, D. Colcher, J. Esteban, 1989, Journal of immunological methods.

Generation, purification, and characterization of a recombinant source of human prostate‐specific antigen

J. Schlom, D. Milenic, S. Kashmiri, 1995, Journal of clinical laboratory analysis.

In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

T. Nayak, M. Brechbiel, D. Milenic, 2011, EJNMMI research.

Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

M. Brechbiel, D. Milenic, K. Baidoo, 2017, Dalton transactions.

Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab

M. Brechbiel, D. Milenic, K. Baidoo, 2017, Translational oncology.

Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.

L. Chappell, M. Brechbiel, P. Albert, 2004, Cancer biotherapy & radiopharmaceuticals.

In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.

S. Mirzadeh, M. Brechbiel, J. Schlom, 2001, Cancer biotherapy & radiopharmaceuticals.

MONICA: a compact, portable dual gamma camera system for mouse whole-body imaging.

Michael V. Green, P. Choyke, J. Seidel, 2010, Nuclear Medicine and Biology.

Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.

T. Yokota, J. Schlom, M. Whitlow, 1993, Cancer research.

Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.

P. Choyke, M. Brechbiel, D. Milenic, 2007, Journal of medicinal chemistry.

Targeting HER2

T. Nayak, M. Brechbiel, D. Milenic, 2010, mAbs.

Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease

M. Brechbiel, P. Albert, D. Milenic, 2004, Clinical Cancer Research.

CHAPTER 1 Antibody Engineering : Optimizing the Delivery Vehicle

D. Milenic, 2010 .

Antibody Engineering: Optimizing the Delivery Vehicle

D. Milenic, 2010 .

Assay for the detection of anti‐idiotypic antibodies to monoclonal antibody b72.3

J. Schlom, P. Ferroni, D. Milenic, 1990, Journal of clinical laboratory analysis.

TAG-72 as a Tumor Marker

M. Kuroki, P. Hand, A. Thor, 1992 .

In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72.

J. Schlom, P. Ferroni, M. Roselli, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.

L. Chappell, M. Brechbiel, E. Dadachova, 2000, Nuclear medicine and biology.

An effective chelating agent for labelling of monoclonal antibody with 212Bi for α-particle mediated radioimmunotherapy

M. Brechbiel, M. Roselli, D. Milenic, 1991 .

An Efficient Bifunctional Decadentate Ligand 3p- C -DEPA for Targeted Alpha Radioimmunotherapy Applications

D. Milenic, K. Baidoo, Hyun A. Song, 2011 .

Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.

T. Yokota, J. Schlom, M. Whitlow, 1992, Cancer research.

Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling.

M. Brechbiel, D. Milenic, C. Lai, 2008, Bioconjugate chemistry.

Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

M. Brechbiel, P. Albert, D. Milenic, 2011, Pharmaceuticals.

Gene expression profiling upon 212Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model

M. Brechbiel, D. Milenic, K. Baidoo, 2013, Cancer medicine.

Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.

M. Brechbiel, P. Albert, D. Milenic, 2005, Cancer biotherapy & radiopharmaceuticals.

Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.

L. Chappell, M. Brechbiel, V. Venditto, 2003, Nuclear medicine and biology.

Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide‐labeled immunoconjugates

J. Schlom, M. Schott, D. Milenic, 1994, Cancer.

In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.

S. Mirzadeh, M. Brechbiel, J. Schlom, 1999, Cancer biotherapy & radiopharmaceuticals.

In vitro and in vivo pre-clinical analysis of a F ( ab ’ ) 2 fragment of panitumumab for molecular imaging and therapy of HER 1-positive cancers

T. Nayak, M. Brechbiel, D. Milenic, 2011 .

Synthesis, Characterization, and Biological Evaluation of Integrin α v β 3 -Targeted PAMAM Dendrimers

M. Brechbiel, M. Bernardo, D. Milenic, 2008 .

Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies

M. Brechbiel, M. Roselli, D. Milenic, 1995 .

Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.

M. Brechbiel, D. Milenic, K. Baidoo, 2013, Nuclear medicine and biology.

Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications.

M. Brechbiel, D. Milenic, K. Baidoo, 2011, Bioconjugate chemistry.

Synthesis and biological evaluation of a novel decadentate ligand DEPA.

M. Brechbiel, D. Milenic, K. Baidoo, 2008, Bioorganic & medicinal chemistry letters.

Targeting strategies for cancer radiotherapy.

M. Mayo, L. Chappell, M. Brechbiel, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging.

M. Brechbiel, D. Milenic, K. Baidoo, 2012, Bioorganic & medicinal chemistry letters.

Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper.

M. Brechbiel, D. Milenic, E. Brady, 2004, Nuclear medicine and biology.

Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.

M. Brechbiel, P. Albert, D. Milenic, 2010, Cancer.

Abstract 1601: Paclitaxel potentiates212Pb-radioimmunotherapy-induced cell killing efficacy by perturbing mitotic spindle checkpoint.

M. Brechbiel, D. Milenic, K. Baidoo, 2013 .

Purification of cyclotron-produced 203Pb for labeling Herceptin.

M. Brechbiel, D. Milenic, K. Garmestani, 2005, Nuclear medicine and biology.

Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.

M. Brechbiel, J. Shih, D. Milenic, 2013, Cancer biotherapy & radiopharmaceuticals.

Antibody guided precision radiation therapy.

M. Brechbiel, D. Milenic, E. Brady, 2004, Discovery medicine.

Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model

M. Brechbiel, D. Milenic, K. Baidoo, 2016, PloS one.

Improved efficacy of α‐particle–targeted radiation therapy

M. Brechbiel, P. Albert, D. Milenic, 2010 .

Increases the Ratio of T + Vaccine-Mediated Antigen-Specific CD 8 IL-2 / Anti-IL-2 Antibody Complex Enhances

J. Schlom, H. Sabzevari, D. Milenic, 2008 .

Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.

M. Brechbiel, D. Milenic, K. Garmestani, 2006, Journal of medicinal chemistry.

Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics.

M. Brechbiel, D. Milenic, K. Garmestani, 2002, Journal of medicinal chemistry.

(111)In- and (203)Pb-Labeled Cyclic RGD Peptide Conjugate as an α(v)β(3) Integrin-Binding Radiotracer.

M. Brechbiel, D. Milenic, K. Baidoo, 2012, Journal of labelled compounds & radiopharmaceuticals.

Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).

P. Hand, J. Schlom, D. Milenic, 1993, Biotechnology therapeutics.

Novel synthetic peptide scaffolds for multivalent-targeted imaging agents

P. Choyke, M. Brechbiel, D. Milenic, 2006 .

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

K. Pienta, J. Montie, D. Smith, 1999, Urology.

Radioimmunotherapy: designer molecules to potentiate effective therapy.

D. Milenic, 2000, Seminars in radiation oncology.

Improved tumor radioimmunodetection using a single-chain Fv and gamma-interferon: potential clinical applications for radioimmunoguided surgery and gamma scanning.

J. Carrasquillo, D. Milenic, J. Greiner, 1995, Cancer research.

212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint

M. Brechbiel, D. Milenic, K. Baidoo, 2013, British Journal of Cancer.

PET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A″‐DTPA‐bevacizumab

T. Nayak, M. Brechbiel, D. Milenic, 2011, International journal of cancer.

Quantitative PET imaging of cancer using the human anti-HER1 monoclonal antibody, panitumumab labeled with Y86

M. Brechbiel, D. Milenic, K. Garmestani, 2009 .

New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma.

F. Guadagni, K. D. Hardman, J. Schlom, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging.

M. Brechbiel, D. Milenic, C. Lai, 2009, Bioorganic & medicinal chemistry.

Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease

M. Brechbiel, P. Albert, D. Milenic, 2008, Clinical Cancer Research.

In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response.

J. Schlom, S. Abrams, D. Milenic, 1997, Cancer gene therapy.

Improved Tumor Radioimmunodetection Using a Single-Chain Fv and γ-Interferon: Potential Clinical Applications for Radioimmunoguided Surgery and γ Scanning

Jorge A. Carrasquillo, J. Schlom, J. Carrasquillo, 1995 .

Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.

J. Schlom, D. Milenic, D. Houchens, 1991, Cancer research.

An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

K. D. Hardman, J. Schlom, M. Whitlow, 1993, Protein engineering.

HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts

T. Nayak, M. Brechbiel, D. Milenic, 2011, PloS one.

212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease

M. Brechbiel, D. Milenic, K. Baidoo, 2012, Molecular Cancer Therapeutics.

IL-2/Anti-IL-2 Antibody Complex Enhances Vaccine-Mediated Antigen-Specific CD8+ T Cell Responses and Increases the Ratio of Effector/Memory CD8+ T Cells to Regulatory T Cells1

J. Schlom, H. Sabzevari, D. Milenic, 2008, The Journal of Immunology.

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

E. Padlan, J. Schlom, D. Milenic, 2001, Critical reviews in oncology/hematology.

Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation

James B. Mitchell, T. Waldmann, M. Brechbiel, 2004, Clinical Cancer Research.

Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.

E H Holmes, P L Choyke, P. Choyke, 2009, Current radiopharmaceuticals.

Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

J. Schlom, M. Roselli, M. Bodmer, 1989, Cancer research.

Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only

E. Padlan, J. Schlom, D. Milenic, 2000, The Journal of Immunology.

Antibody Variant by Retention of SDRs Only Development of a Minimally Immunogenic Specificity-Determining Residues (SDRs) and Antibody: Identification of Structural Correlates of an Anticarcinoma

E. Padlan, J. Schlom, D. Milenic, 2000 .

Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

T. Yokota, J. Schlom, M. Whitlow, 1991, Cancer research.

Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.

G. Curt, J. Schlom, J. Grem, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies.

J. Schlom, D. Milenic, D. Colcher, 1992, Targeted diagnosis and therapy.

Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein.

T. Waldmann, M. Brechbiel, D. Milenic, 2006, Nuclear medicine and biology.

Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.

T. Waldmann, M. Brechbiel, D. Milenic, 2004, Nuclear medicine and biology.

Improved speciation characteristics of PEGylated indocyanine green-labeled Panitumumab: revisiting the solution and spectroscopic properties of a near-infrared emitting anti-HER1 antibody for optical imaging of cancer.

M. Brechbiel, D. Milenic, A. J. L. Villaraza, 2010, Bioconjugate chemistry.

Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial

M. Brechbiel, D. Milenic, K. Baidoo, 2015, Pharmaceuticals.

A water-soluble triiodo amino acid and its dendrimer conjugate for computerized tomography (CT) imaging

M. Brechbiel, D. Milenic, S. Walbridge, 2005 .

In Vitro and In Vivo Analysis of Indocyanine Green-Labeled Panitumumab for Optical Imaging—A Cautionary Tale

M. Brechbiel, D. Milenic, K. Baidoo, 2014, Bioconjugate chemistry.

Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability

James B. Mitchell, M. Brechbiel, Hisataka Kobayashi, 2003 .

Novel Iodinated Dendritic Nanoparticles for Computed Tomography (CT) Imaging

Martin W. Brechbiel, M. Brechbiel, N. Patronas, 2002 .

Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.

M. Brechbiel, D. Milenic, D. Cheng, 2008, Bioconjugate chemistry.

Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.

S. Kennel, S. Mirzadeh, M. Brechbiel, 2002, Cancer biotherapy & radiopharmaceuticals.